Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tilray Brands Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while Tilray Brands Inc trades at $3.1 (market cap $463.31M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 15.9× Tilray Brands Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| SYRE | TLRY | |
|---|---|---|
Market Cap | $7.35B | $463.31M |
Volume | 1,624,631 | 4,627,093 |
Sector | Health | Health |
52-Week High | $108.92 | $16.80 |
52-Week Low | $22.18 | $3.14 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $6.35B | $617.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TLRY trades at $3.27, down 2.68% on the day and near 52-week lows, reflecting persistent bearish pressure. The stock's technical indicators are mixed but overall signal remains negative. Fundamentally, the company reported a net loss of $2.19 billion in 2025 despite $821 million in revenue, with profitability metrics deeply negative. Recent news highlights continued stock weakness and strategic brand expansions under Tilray ownership.
The outlook is highly speculative; TLRY faces significant execution and profitability challenges, though analyst consensus suggests substantial upside potential from current levels. Key risks include ongoing losses, high debt levels, and regulatory uncertainty in the cannabis sector. Investment suitability is limited to high-risk tolerance investors betting on a operational turnaround or favorable regulatory shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
